Nephrogenic systemic fibrosis and the role of gadolinium contrast media

Journal of Medical Imaging and Radiation Oncology

Volumn 52, Issue 4, 2008, Pages 339-350

  Van Der Molen, A J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse effects; Contrast media; Gadodiamide; Gadolinium; Gadopentetate; Gadoversetamide; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis

Indexed keywords

CORTICOSTEROID; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; IMMUNOGLOBULIN; PENTOXIFYLLINE; PSORALEN; SODIUM THIOSULFATE; THALIDOMIDE;

DIFFERENTIAL DIAGNOSIS; DRUG STABILITY; ELECTROLYTE DISTURBANCE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LIVER TRANSPLANTATION; NEPHROGENIC FIBROSING DERMOPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIATION DOSE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; ULTRAVIOLET A RADIATION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR PROBE TECHNIQUES; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 52049097295     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1440-1673.2008.01965.x     Document Type: Review

References (83)

1. Lin SP, Brown JJ. MR contrast agents: physical and pharmacological basics. J Magn Reson Imaging 2007 25 : 884 99.
2. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003 14 : 426 35.
3. Bellin MF. MR contrast agents: the old and the new. Eur J Radiol 2006 60 : 314 23.
4. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization of pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006 41 : 491 99.
5. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007 42 : 58 62.
6. Spinosa DJ, Kaufmann JA, Hartwell GD. Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 2002 223 : 319 27.
7. Strunk HM, Schild H. Actual clinical use of gadolinium-chelates for non-MRI applications. Eur Radiol 2004 14 : 1055 62.
8. Remy-Jardin M, Bahepar J, Lafitte JJ, et al. Multi-detector row CT angiography of pulmonary circulation with gadolinium-based contrast agents: prospective evaluation in 60 patients. Radiology 2006 238 : 1022 35.
9. Elmstahl B, Nyman U, Leander P, Chai CM, Frennby B, Almen T. Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. Acad Radiol 2004 11 : 1219 28.
10. Elmstahl B, Nyman U, Leander P, et al. Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections. Eur Radiol 2006 16 : 2712 20 Erratum in : Eur Radiol 2006 16 : 28 84).
11. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 21 : 1104 8 Erratum in : Nephrol Dial Transplant 2006 21 : 17 45).
12. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000 356 : 1000 1.
13. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001 23 : 383 93.
14. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003 139 : 903 6.
15. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006 54 (2 Suppl S31 S34.
16. Gibson SE, Farver C, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006 130 : 209 12.
17. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006 35 : 238 49.
18. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005 46 : 754 59.
19. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007 23 : 131 54.
20. Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol 2008 5 : 23 8.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 (2 Suppl 1 S1 S266.
22. Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 2007 29 : 433 36.
23. Swaminathan S, Shah SV. New insights into nehrogenic systemic fibrosis. J Am Soc Nephrol 2007 18 : 2636 43.
24. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 17 : 2359 62.
25. Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008 51 : 966 75 (preliminary report in : MMWR Morb Mortal Wkly Rep 2007 56 : 137 41).
26. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007 188 : 586 92.
27. Khurana A, Runge VM, Narayanan M, Greene JF Jr., Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007 42 : 139 45.
28. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examing the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007 2 : 264 7.
29. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007 243 : 148 57.
30. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: A clinico-pathologic study of six cases. J Am Acad Dermatol 2007 57 : 105 11.
31. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007 22 : 3174 8.
32. Collidge TA, Thompson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement cohort. Radiology 2007 245 : 168 75.
33. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007 143 : 1025 30 Erratum in : Arch Dermatol 2007 143 : 15 65).
34. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007 56 : 3433 41.
35. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007 22 : 3179 85 Erratum in : Nephrol Dial Transplant 2008 23 : 14 67 TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007 26 : 1198 203.
36. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008 43 : 141 4.
37. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008 190 : 736 41.
38. Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, et al. Gadolinium-based contrast exposure, Nephrogenic Systemic Fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008 190 : 1060 8.
39. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008 43 : 65 75.
40. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006 145 : 234 5.
41. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007 357 : 720 22.
42. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006 6 : 2212 7.
43. Cacetta T, Chan JJ. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium. Aust J Dermatol 2008 49 : 48 51.
44. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007 7 : 2425 32.
45. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008 158 : 273 80.
46. Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR) cited 15 Feb 2008 Available at : www.icnfdr.org
47. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007 242 : 647 9.
48. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006 16 : 2619 21.
49. ®) in patients on chronic hemodialysis. Clin J Am Soc Nephrol 2008 3 : 747 51.
50. Karie S, Janus M, Launay-Vacher V, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Abstract B-098 European Congress of Radiology 2008. Eur Radiol 2008 18 (Suppl 1 162.
51. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007 80 : 73 6.
52. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008 21 : 469 90.
53. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006 20 : 563 76.
54. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992 27 (Suppl 1 S2 S6.
55. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995 30 : 372 80.
56. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007 56 : 27 30.
57. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest Radiol 2006 41 : 272 8.
58. High WA, Ayers RA, Cowper SE. Gadolinium is quantifyable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 710 12.
59. Kimura J, Ishguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005 23 : 322 6.
60. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001 36 : 115 22.
61. Laurent S, van der Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Med Mol Imaging 2006 1 : 128 37.
62. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of Gd complexes. Magn Reson Imaging 1990 8 : 467 81.
63. Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007 25 : 881 3.
64. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996 31 : 739 42.
65. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents [letter]. Br J Radiol 2007 80 : 581 82 author reply 584-5.
66. Port M, Idee JM, Medina C, Dencausse A, Corot C. Stability of gadolinium chelates and their biological consequences: new data and some comments [letter]. Br J Radiol 2008 81 : 258 9.
67. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005 40 : 715 24.
68. Stenver DI. Pharmacovigilance: what to do when you see an adverse reaction and the consequences. Eur J Radiol 2008 66 : 184 6.
69. Stenver DI. Investigation of the safety of MRI contrast medium Omniscan. Danish Medicines Agency, May 29, 2006. Available at : http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=8931 Accessed: 15 february 2008.
70. U.S. Food and Drug Administration. Public health advisory: Update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. Updated December 22, 2006 and May 23, 2007. Available at : http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705HCP.pdf Accessed: 15 february 2008.
71. European Medicines Agency. Nephrogenic Systemic Fibrosis (NSF) with the gadolinium-containing MRI contrast agents - update June 26, 2007. Available at : http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGEampuseSecondary= trueampssDocName=CON2031543ampssTargetNodeId=221 Accessed: 15 february 2008.
72. Kanal E, Barkovich AJ, Bell C, et al. for the ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007 188 : 1447 74 (ACR editorial by Van Moore A AJR Am J Roentgenol 2007 188 : 14 46).
73. Thomsen HS. ESUR Guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007 17 : 2692 6.
74. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between Gadolinium-based contrast agents? Semin Dialysis 2008 21 : 129 34.
75. Nephrogenic systemic fibrosis: an uncommon and debilitating disease possibly associated with gadolinium chelates. Update 21 december 2007. Available at : http://www.guerbet.com/fileadmin/user_upload/news/ Updated_information_about_NSF_21_dec_2007.pdf Accessed: 15 february 2008.
76. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008 246 : 11 4.
77. Saab G, Abu-Alfa A. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? [Letter]. Radiology 2007 244 : 930 1.
78. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 1998 5 : 491 502.
79. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006 24 : 445 51.
80. Okada S, Katagiri K, Kumazaki T, et al. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001 42 : 339 41.
81. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 2002 178 : 105 9.
82. Ueda J, Furukawa T, Higashino K, et al. Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. Eur J Radiol 1999 31 : 76 80.
83. Rodby RA. Dialytic therapies to prevent NSF following Gadolinium exposure in high risk patients. Semin Dialysis 2008 21 : 145 9.